Results 61 to 70 of about 1,312,052 (154)

Efficacy of tumor necrosis factor inhibitors in hand osteoarthritis: A systematic review and meta-analysis of randomized controlled trials

Osteoarthritis and Cartilage Open, 2023
Objectives: This study aimed at systematically review the evidence for the efficacy of Tumor Necrosis Factor (TNF) inhibitors on symptoms and structural outcomes in hand osteoarthritis.
Mahnuma Mahfuz Estee, Flavia M. Cicuttini, Matthew J. Page, Anita E. Wluka, Yuanyuan Wang   +4 more
doaj   +1 more source

Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort [PDF]

, 2022
To compare real-world persistence, effectiveness and tolerability of ustekinumab versus TNF inhibitors (TNFi) in psoriatic arthritis (PsA)
Iannone, Florenzo, Idolazzi, Luca, Smolen, Josef, Fusaro, Enrico, Delle Sedie, Andrea, Gossec, Laure, Smolen, Josef S, Ciccia, Francesco, Cuomo, Giovanna, Perricone, Roberto, Noël, Wim, Conti, Fabrizio, Bergmans, Paul, Gremese, Elisa, Guggino, Giuliana, Selmi, Carlo, Foti, Rosario, Matucci-Cerinic, Marco, Marelli, Silvia, Smolen, Josef S., Theander, Elke, Moscato, Paolo, Gremese, E.   +22 more
core   +1 more source

Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement

Reumatismo, 2023
Psoriatic arthritis (PsA) is an inflammatory disease characterized by peripheral and axial involvement. Biological disease-modifying antirheumatic drugs (bDMARDs) are the mainstream treatment for PsA and bDMARDs retention rate is a proxy for the drug’s ...
G. Adami, L. Idolazzi, C. Benini, E. Fracassi, A. Carletto, O. Viapiana, D. Gatti, M. Rossini, A. Fassio   +8 more
doaj   +1 more source

TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis

Frontiers in Immunology, 2022
With anti-PD-1 antibodies serving as a representative drug, immune checkpoint inhibitors (ICIs) have become the main drugs used to treat many advanced malignant tumors.
Xiaohang Liu, Wei Wu, Ligang Fang, Yingxian Liu, Wei Chen   +4 more
doaj   +1 more source

Risk of New-Onset Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor Inhibitors Treatment for Autoimmune Diseases: A Systematic Review and Meta-Analysis

Journal of Clinical Rheumatology and Immunology
Background: Tumor necrosis factor (TNF) inhibitors have been extensively utilized to treat various autoimmune diseases. However, there are ongoing debates about the risk of inflammatory central nervous system (CNS) diseases events following TNF ...
Wenhui Xie
doaj   +1 more source

Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor-α Inhibitor Induction Therapy among Patients with Crohn’s Disease

Inflammatory Intestinal Diseases, 2020
Induction therapy with tumor necrosis factor-α (TNF-α) inhibitors is highly effective for the treatment of Crohn’s disease. However, there are primary nonresponders (PNR) of TNF-α inhibitors without clinical response during the induction period.
Hideki Iijima, Taku Kobayashi, Mitsuo Nagasaka, Shinichiro Shinzaki, Kazuya Kitamura, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi   +7 more
doaj   +1 more source

Clinical Outcomes in Iraqi Patients with Rheumatoid Arthritis Following Earlier or Later Treatment with Etanercept

Open Access Rheumatology: Research and Reviews, 2021
Nizar Al-Ani,1 Faiq Gorial,1 Dina Yasiry,2 Fadya Al Derwibee,2 Yasameen Abbas Humadi,3 Nancy Sunna,4 Ali AlJabban5 1Rheumatology Unit, College of Medicine, University of Baghdad, Baghdad, Iraq; 2Department of Rheumatology, Baghdad Teaching Hospital ...
Al-Ani N, Gorial F, Yasiry D, Al Derwibee F, Abbas Humadi Y, Sunna N, AlJabban A   +6 more
doaj  

Structure-based repurposing of FDA-approved drugs as TNF-α inhibitors

, 2011
Old dogs, new tricks! We applied structure-based virtual screening methods to identify small-molecule inhibitors of tumor necrosis factor-α (TNF-α) from a database of 3000 US Food and Drug Administration (FDA)-approved drugs.
Cheng, Z, Ma, DL, Chan, DSH, Zhu, GY, Wong, CY, Kwan, MHT, Leung, CH, Fong, WF   +7 more
core   +1 more source

Demographic and clinical characteristics of RA and AS patients starting the originator and biosimilar TNF inhibitors.

, 2020
Demographic and clinical characteristics of RA and AS patients starting the originator and biosimilar TNF inhibitors.
Seul Gi Im (4902652), Sun-Young Jung (295962), Yoon-Kyoung Sung (2503147), Soo-Kyung Cho (219556), Hyoungyoung Kim (7400207), Seongmi Choi (7400210), Eun Jin Jang (2591209), Yu Sang Lee (8356854)   +7 more
core   +1 more source

Certolizumab pegol – new option in the treatment of psoriatic arthritis

Rheumatology, 2014
It has been proven that tumor necrosis factor (TNF) plays an important role in the pathophysiology of psoriatic arthritis (PsA). TNF inhibitors have been demonstrated to improve the skin and joint manifestations of psoriasis.
Maria Majdan, Anna Siwiec, Aleksandra Gryta   +2 more
doaj   +1 more source